US FDA Opinions Vary On AI’s Black Box Issues. Will Uncertainty Follow?

 
• By Derrick Gingery
  
Transparency is important with an AI black box, the FDA said. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from AI

More from Pathways & Standards